Oncotarget releases new study on therapeutic treatment for breast cancer patients

Aggressive breast cancer study shows that a more therapeutic treatment could be in the future for those who have the hormone “ERB” (Estrogen Receptor Bata). Oncotarget has also published an article that is targeting specific molecules for further research. These molecules could provide better medications for those with breast cancer. Those that have been diagnosed with “TNBC” (Triple Negative Breast Cancer) are also considered Aggressive types. 15 percent of those diagnosed cancer types lose the proteins that bind the hormones estrogen and progesterone that is present in normal breast cells. The lose of these receptors makes cancers more resistant to common treatments. Learn more about Oncotarget at Research Gate.

Considering all the new advancements in treatment methods TBNC patients are not properly diagnosed since the cancer is likely to spread to other organs. Researchers are working on understanding the characteristics of the cells and molecular pathways to identify the best treatment options. The research involving introducing estrogen to cancer cells could show a reduction of the cancer tumors or prevent their growth. These finding will be further evaluated before they are considered for clinical trial.

Visit: https://oncotarget.msubmit.net/cgi-bin/main.plex

Oncotarget recently awarded four biomedical researchers grants to attend a cancer science conference in Singapore. The four researchers were committed to discussing the advancements in cancer science.

At the (Frontiers in Cancer Science 2017) scientists from around the world gathered to discuss recent findings in cancer research. Oncotarget was not only proud to provide that opportunity to the researchers. Oncotarget is for the pursuit, maximization and the circulation of science discovery information. Follow Oncotarget journal on Twitter.

Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science